Immunotherapy for Malignant Glioma: Current Status and Future Directions
- 1 February 2020
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 41 (2) , 123-138
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81902538, 81872072)
- Shanghai Sailing Program (19YF1448200)
- National Key Research and Development Program of China (2017FYA0205302)
This publication has 101 references indexed in Scilit:
- A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic ResponsesMolecular Therapy, 2014
- Optogenetic control of chemokine receptor signal and T-cell migrationProceedings of the National Academy of Sciences, 2014
- Sox2 Is Required to Maintain Cancer Stem Cells in a Mouse Model of High-Grade OligodendrogliomaCancer Research, 2014
- CSF-1R inhibition alters macrophage polarization and blocks glioma progressionNature Medicine, 2013
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunology, Immunotherapy, 2012
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaNeuro-Oncology, 2010
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed GlioblastomaJournal of Clinical Oncology, 2010
- B7-H1–Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy ResponsesThe Journal of Immunology, 2010
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006